Brain-derived neurotrophic factor concentrations in the cerebrospinal fluid of patients with Parkinson's disease

Journal of Clinical Neuroscience

Volumn 16, Issue 1, 2009, Pages 90-93

  Salehi, Zivar ^a   Mashayekhi, Farhad ^a  

^a UNIVERSITY OF GUILAN   (Iran)

Author keywords

Brain derived neurotrophic factor; Cerebrospinal fluid; Parkinson's disease

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR;

ADULT; AGED; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CONTROL GROUP; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

AGED; BLOTTING, WESTERN; BRAIN-DERIVED NEUROTROPHIC FACTOR; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE;

EID: 56949096510     PISSN: 09675868     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jocn.2008.03.010     Document Type: Article

References (31)

1. Gibb W.R., and Lees A.J. Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease. J Neurol Neurosurg Psychiatry 54 (1991) 388-396
2. Seo W.K., Koh S.B., Kim B.J., et al. Prevalence of Parkinson's disease in Korea. J Clin Neurosci 14 (2007) 1155-1157
3. Nutt J.G., and Wooten G.F. Clinical practice. Diagnosis and initial management of parkinson's disease. N Engl J Med. 353 (2005) 1021-1027
4. Kuzuhara S., Mori H., Izumiyama N., et al. Lewy bodies are ubiquitinated. A light and electron microscopic immunocytochemical study. Acta Neuropathol 75 (1988) 345-353
5. Nishimura M., Tomimoto H., Suenaga T., et al. Synaptophysin and chromogranin A immunoreactivities of Lewy bodies in Parkinson's disease brains. Brain Res 634 (1994) 339-344
6. Korhonen L., Riikonen R., Nawa H., et al. Brain derived neurotrophic factor is increased in cerebrospinal fluid of children suffering from asphyxia. Neurosci Lett 240 (1998) 151-154
7. Xia Y.X., Ikeda T., Xia X.Y., et al. Differential neurotrophin levels in cerebrospinal fluid and their changes during development in newborn rat. Neurosci Lett 280 (2000) 220-222
8. Albrecht D., Garci{dotless}́a L., Cartier L., et al. Trophic factors in cerebrospinal fluid and spinal cord of patients with tropical spastic paraparesis, HIV, and Creutzfeldt-Jakob disease. AIDS Res Hum Retroviruses 22 (2006) 248-254
9. Parain K., Murer M.G., Yan Q., et al. Reduced expression of brain-derived neurotrophic factor protein in Parkinson's disease substantia nigra. Neuroreport 10 (1999) 557-561
10. Mogi M., Togari A., Kondo T., et al. Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson's disease. Neurosci Lett 270 (1999) 45-48
11. Murer M.G., Yan Q., and Raisman-Vozari R. Brain-derived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's disease. Prog Neurobiol 63 (2001) 71-124
12. Hyman C., Hofer M., Barde Y.A., et al. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 350 (1991) 230-232
13. Teunissen C.E., de Vente J., Steinbusch H.W., et al. Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid. Neurobiol Aging 23 (2002) 485-508
14. Yasui K., Inoue Y., Kanbayashi T., et al. CSF orexin levels of Parkinson's disease, dementia with Lewy bodies, progressive supranuclear palsy and corticobasal degeneration. J Neurol Sci 250 (2006) 120-123
15. Abdi F., Quinn J.F., Jankovic J., et al. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis 9 (2006) 293-348
16. Laterza O.F., Modur V.R., Crimmins D.L., et al. Identification of novel brain biomarkers. Clin Chem 52 (2006) 1713-1721
17. El-Agnaf O.M., Salem S.A., Paleologou K.E., et al. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J 20 (2006) 419-425
18. Yu S.J., Lo E.S., Cochran E.J., et al. Cerebrospinal fluid from patients with Parkinson's disease alters the survival of dopamine neurons in mesencephalic culture. Exp Neurol 126 (1994) 15-24
19. Altar C.A., Boylan C.B., Jackson C., et al. Brain-derived neurotrophic factor augments rotational behavior and nigrostriatal dopamine turnover in vivo. Proc Natl Acad Sci USA 89 (1992) 11347-11351
20. Sauer H., Fischer W., Nikkhah G., et al. Brain-derived neurotrophic factor enhances function rather than survival of intrastriatal dopamine cell-rich grafts. Brain Res 626 (1993) 37-44
21. Sauer H., Campbell K., Wiegand S.J., et al. Brain-derived neurotrophic factor enhances striatal neuropeptide expression in both the intact and the dopamine-depleted rat striatum. Neuroreport 5 (1994) 609-612
22. Yoshimoto Y., Lin Q., Collier T.J., et al. Astrocytes retrovirally transduced with BDNF elicit behavioral improvement in a rat model of Parkinson's disease. Brain Res 691 (1995) 25-36
23. Plunkett R.J., Ip N.Y., Asada H., et al. Trauma-induced striatal CNTF and BDNF mRNA in hemiparkinsonian rats. Neuroreport 8 (1997) 507-511
24. Tang F.I., Tien L.T., Zhou F.C., et al. Intranigral ventral mesencephalic grafts and nigrostriatal injections of glial cell line-derived neurotrophic factor restore dopamine release in the striatum of 6-hydroxydopamine-lesioned rats. Exp Brain Res 119 (1998) 287-296
25. Yurek D.M., and Fletcher-Turner A. Lesion-induced increase of BDNF is greater in the striatum of young versus old rat brain. Exp Neurol 161 (2000) 392-396
26. Nishimura M., Kuno S., Kaji R., et al. Brain-derived neurotrophic factor gene polymorphisms in Japanese patients with sporadic Alzheimer's disease, Parkinson's disease, and multiple system atrophy. Mov Disord 20 (2005) 1031-1033
27. Chen C.M., Chen I.C., Chang K.H., et al. Nuclear receptor NR4A2 IVS6 + 18insG and brain derived neurotrophic factor (BDNF) V66M polymorphisms and risk of Taiwanese Parkinson's disease. Am J Med Genet B Neuropsychiatr Genet 144 (2007) 458-462
28. Tsai S.J. Glatiramer acetate could be a potential therapeutic agent for Parkinson's disease through its neuroprotective and anti-inflammatory effects. Med Hypotheses 69 (2007) 1219-1221
29. Guillin O., Griffon N., Bezard E., et al. Brain-derived neurotrophic factor controls dopamine D3 receptor expression: therapeutic implications in Parkinson's disease. Eur J Pharmacol 480 (2003) 89-95
30. Knott C., Stern G., Kingsbury A., et al. Elevated glial brain-derived neurotrophic factor in Parkinson's diseased nigra. Parkinsonism Relat Disord 8 (2002) 329-341
31. Sawada M., Imamura K., and Nagatsu T. Role of cytokines in inflammatory process in Parkinson's disease. J Neural Transm Suppl (2006) 373-381